Form 4: Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, Executes Stock Option and Sells Shares Under 10b5-1 Plan
SEC Form 4
Timothy Rolph, Chief Scientific Officer of Akero Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.
Summary
- On April 7, 2025, Timothy Rolph, the Chief Scientific Officer of Akero Therapeutics, exercised a stock option to acquire 6,250 shares of common stock at a price of $21.10 per share.
- Rolph also sold a total of 6,250 shares of Akero Therapeutics common stock in multiple transactions at weighted-average prices ranging from $35.356 to $37.915.
- These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2024.
- Following these transactions, Rolph directly owns 169,721 shares of Akero Therapeutics common stock and 28,718 derivative securities (stock options).
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider trading activity. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions. It is common for executives to utilize 10b5-1 plans to sell shares over time to avoid accusations of trading on inside information. The filing itself doesn't provide specific insight into Akero's operational performance or strategic direction.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 2021-12-08 | Stock option vesting commences in 48 equal monthly installments. |
| 2024-08-12 | Date of adoption of Rule 10b5-1 trading plan. |
| 2025-04-07 | Date of stock option exercise and share sales. |
| 2025-04-10 | Date of signature on the Form 4 filing. |
| 2031-12-07 | Expiration date of the stock options. |
Keywords
Akero Therapeutics, Timothy Rolph, stock options, Form 4, Rule 10b5-1, insider trading, AKRO, Chief Scientific Officer, share sales
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.